Effect of angiotensin II on the antitumor activity and cardiotoxicity of doxorubicin.
The effects of angiotensin II (AII) on the antitumor activity and cardiotoxicity of doxorubicin (DXR) were tested in rats bearing Walker 256/A carcinoma. The animals received 2, 4 or 6 mg/kg of DXR as a bolus i.v. injection, with or without a concurrent i.v. infusion of 2 micrograms/kg/min of AII, starting 1 h prior to DXR administration for a total of 6 h. Neither the antitumor activity, nor the myocardial toxicity of DXR, as assessed by ECG evaluation (Q alpha T duration), were affected by AII at the tested dose. 100% of the animals receiving 6 mg/kg of DXR with or without AII were cured from the tumor, but subsequently some of them developed toxic signs and eventually died within the 12th week after treatment. Rats receiving DXR + AII showed a higher long-term survival than those receiving DXR alone; therefore, a possible interference with other DXR-induced side effects, such as nephrotoxicity, is hypothesized.
Monti
E
E
Istituto di Farmacologia, Facolta di Scienze, Universita di Milano, Italy.
Paracchini
L
L
Piccinini
F
F
Rossi
C
C
Formelli
F
F
D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004317:Doxorubicin / Q000627:therapeutic use / Q000633:toxicity*; D005260:Female; D006321:Heart / Q000187:drug effects*; D007668:Kidney / Q000187:drug effects; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D051381:Rats; D011919:Rats, Inbred Strains
D000804:Angiotensin II; D004317:Doxorubicin